AbbVie Aktie News

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Seattle NORTH CHICAG...

All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal health agency said on Friday.

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.

AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million upfront for GUBamy, with potential milestones up to $1.875 billion, and royalties on net sales. Amylin analogs like GUBamy offer promising weight loss effects (albeit not at the levels of leading inc...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.

This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.

AbbVie Inc. (NYSE:ABBV ) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - EVP, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Rob Michael - Chief Executive Officer Conference Call Participants David Risi...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.